SANTA CLARA, CALIFORNIA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- On February 10, 2025, Avinger, Inc., a Delaware Corporation (“Avinger” or the “Company”), entered into a general assignment for the benefit of creditors (the “Assignment”) in favor of Avinger (assignment for the benefit of creditors), LLC, a California limited liability company (the “Assignee”). Pursuant to the Assignment, the Company transferred substantially all of the Company’s assets to the Assignee for liquidation. The Assignee will, as appropr ...

Avinger, Inc. (NASDAQ:AVGR) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Matthew Kreps - Investor Relations Jeffrey Soinski - Chief Executive Officer Nabeel Subainati - Principal Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and welcome to the Avinger Third Quarter 2024 Results Conference Call. At this time, all participants are on a listen-only mode. After managements prepared remarks, there will be a question ...

Avinger (AVGR) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $2.03. This compares to loss of $2.92 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 10.34%. A quarter ago, it was expected that this medical device maker would post a loss of $0.43 per share when it actually produced a loss of $2.82, delivering a surprise of -555.81%. Over the last four quarters, the company has ...

Financial Performance - Reported third quarter 2024 revenue of $1.7 million, with a gross margin of 26%, an increase from 20% in the previous quarter[2] - Revenues for the three months ended September 30, 2024, were $1,650,000, a decrease of 10.7% from $1,847,000 for the same period in 2023[19] - Gross profit for the three months ended September 30, 2024, was $426,000, representing a 12.7% increase from $378,000 in the prior year[19] - Net loss improved to $3.7 million, compared to $4.4 million in the second quarter of 2024, marking a 15% reduction in net loss[9] - Net loss for the three months ended September 30, 2024, was $(3,706,000), compared to a net loss of $(4,362,000) for the same period in 2023, reflecting a 15% improvement[20] - The company reported a net loss per share attributable to common stockholders of $(1.82) for the three months ended September 30, 2024, compared to $(2.82) in the same quarter of 2023[19] - Adjusted EBITDA loss improved to $3.4 million, compared to a loss of $3.8 million in the previous quarter[10] - Adjusted EBITDA for the three months ended September 30, 2024, was $(3,371,000), slightly better than $(3,834,000) in the previous quarter[20] Operating Expenses - Operating expenses decreased to $4.1 million, down from $4.5 million in the second quarter of 2024, reflecting a 16% reduction in selling, general and administrative expenses[7][8] - Total operating expenses for the three months ended September 30, 2024, were $4,095,000, down 9.1% from $4,505,000 in the same quarter of 2023[19] - Research and development expenses for the three months ended September 30, 2024, were $1,086,000, an increase of 20.1% from $904,000 in the prior year[19] Cash and Financial Health - Cash and cash equivalents totaled $5.9 million as of September 30, 2024[11] - Cash and cash equivalents increased to $5,901,000 as of September 30, 2024, from $5,275,000 at December 31, 2023[21] - Total current liabilities decreased significantly to $9,503,000 as of September 30, 2024, from $19,300,000 at December 31, 2023, indicating improved financial health[21] - Total assets as of September 30, 2024, were $13,601,000, a slight decrease from $13,770,000 at December 31, 2023[21] Product Development and Regulatory Updates - Initiated full commercial launch of the Pantheris LV image-guided atherectomy device for peripheral arteries[2] - Filed Investigational Device Exemption (IDE) pre-submission package with the U.S. FDA for the coronary CTO-crossing system, with submission anticipated in Q4 2024[2][4] - Zylox received Innovative Medical Device review designation for Pantheris in China, enabling priority regulatory review[5] - Anticipated completion of full manufacturing scale-up for Avinger devices in China by mid-2025[5] - Released clinical data showing 100% freedom from major adverse events at 30 days for Pantheris SV in the IMAGE-BTK study[2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class: Trading Symbol(s): Name of each exchange on which registered: Common Stock, par value $0.001 per share AVGR The Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36 ...

Avinger, Inc. (AVGR) has announced the full commercial launch of its Pantheris LV image-guided directional atherectomy system. It is the first and only image-guided system for treating peripheral artery disease (PAD) in large vessels.The Pantheris LV builds upon the success of Avinger’s Pantheris SV, expanding its application to above-the-knee procedures with advanced features that enhance both performance and usability.Significance of Pantheris LVPer Avinger, the full commercialization of Pantheris LV mark ...

Avinger, Inc. (NASDAQ:AVGR) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Matt Kreps - Investor Relations Jeff Soinski - Chief Executive Officer Nabeel Subainati - Principal Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Welcome to the Avinger Second Quarter 2024 Results Call. At this time, all participants are on a listen-only mode. Later we’ll conduct a question-and-answer session. I'll now turn the call over to your host, ...

Company Performance - Avinger reported a quarterly loss of $2.82 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.43, and an improvement from a loss of $8.85 per share a year ago, indicating a surprise of -555.81% [1] - The company generated revenues of $1.85 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 27.57% and down from $2.04 million in the same quarter last year [1] - Avinger has not surpassed consensus EPS or revenue estimates over the last four quarters [1] Stock Performance - Avinger shares have declined approximately 54.6% since the beginning of the year, contrasting with the S&P 500's gain of 9% [2] - The current Zacks Rank for Avinger is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [4] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.42 on revenues of $2.73 million, and for the current fiscal year, it is -$2.08 on revenues of $10.5 million [4] - The trend of estimate revisions for Avinger is mixed, and future changes in estimates will be closely monitored following the recent earnings report [4] Industry Context - The Medical - Instruments industry, to which Avinger belongs, is currently ranked in the top 42% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [5] - NeuroPace, Inc., another company in the same industry, is expected to report a quarterly loss of $0.29 per share, reflecting a year-over-year change of +19.4%, with revenues projected at $18.72 million, up 13.4% from the previous year [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class: Trading Symbol(s): Name of each exchange on which registered: Common Stock, par value $0.001 per share AVGR The Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36817 A ...

Exhibit 99.1 Avinger Reports Second Quarter 2024 Results Implements Lower Operating Cost Profile, Readying OCT-Guided Coronary Device for IDE Submission Redwood City, Calif., August 8, 2024 - Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the second quarter ended June 30, 2024. Second Quarter and Recent Highlights ...